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Abstract
Background: Metabolic syndrome (MetS) is an important risk factor for cerebral ischemic stroke, yet previous
studies on the relationship between MetS or its components and acute cerebral infarction have been inconsistent.
This study aims to evaluate the effects of MetS and its components on the short-term prognosis of patients with
acute ischemic stroke.
Methods: Subjects with ischemic stroke of <7-day duration (530 cases) were enrolled. MetS was defined based on
the modified criteria of the International Diabetes Federation and the American Heart Association/National Heart,
Lung, and Blood Institute. Demographic data, vascular risk factors, National Institutes of Health Stroke Scale score,
the results of physical, laboratory and imaging examinations and clinical outcomes at 30 and 90 days were
recorded. Using univariate analysis, we compared different baseline characteristics between patients with MetS and
those without MetS. Further, we assessed MetS and its 5 components on the contribution to short-term prognosis
of ischemic stroke with multiple logistic regression models after adjusting for age and sex.
Results: The prevalence of MetS among the patients with acute ischemic stroke in the study is 58.3 %, with more
in females (70.3 %) than in males (49.7 %, p < 0.001). As expected, among the MetS components, elevated waist
circumference, elevated triglyceride, high fasting blood glucose and low high density lipoprotein cholesterol
(HDL-C) were significantly more prevalent in patients with MetS than those without MetS (all p < 0.001). There was
no correlation between MetS itself and the short-term prognosis of acute ischemic stroke. Only hyperglycemia in
the serum was shown to have impact on poor functional outcomes in 30 and 90 days after the onset of stroke.
Conclusions: The occurrence of MetS among patients with acute ischemic stroke in our study is 58.3 %. MetS itself
may not be predictive for the short-term prognosis of patients, while hyperglycemia is a significant predictor for
poor functional outcomes in our study.
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Background
Stroke has been the most important cause for disability
and clinical death because of its high prevalence, mor-
bidity and recurrence in China [1]. Multiple risk factors
are involved in the progress of acute cerebrovascular
diseases, including unmodifiable risk factors, such as age,
gender, race/ethnicity and heredity, and modifiable risk
factors, such as hypertension, diabetes mellitus, atrial
fibrillation and other cardiac diseases, dyslipidemia,
asymptomatic carotid stenosis, obesity, unhealthy lifestyle,
metabolic syndrome (MetS) etc.
MetS can be defined as a constellation of interrelated
metabolic abnormalities that increases the risk of cerebro-
vascular diseases. It includes insulin resistance/diabetes,
elevated blood pressure, obesity, and dyslipidemia [2].
The insulin resistance is deemed as the primary
pathomechanism of MetS, according to World Health
Organization diagnostic criteria [3]. Numerous epidemio-
logic and clinical studies indicated that MetS was highly
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correlated to the occurrence of stroke [4–6], even recur-
rence [7, 8]. Persons with MetS have a significantly higher
risk of incident ischemic stroke than those with no MetS.
After adjusting other risk factors, the number of MetS
components is highly correlated to the risk of ischemic
stroke incidence [9, 10]. However, less information is avail-
able in China on the potential relationship between MetS
including its components and short-term outcomes of
acute ischemic stroke. Thus, the present study aims to in-
vestigate the effects of MetS and its individual components
on ischemic stroke, and their impact on the short-term out-
comes of acute ischemic stroke among our hospitalized
patients.
Results
Baseline characteristics of the patients
Baseline characteristics of acute ischemic patients with or
without MetS are presented in Table 1. Five hundred and
thirty participants (222 women) with the average age of
69.3 ± 11.2 (from 30 to 94 years old) were enrolled in this
study, in which 309 (58.3 %) patients met criteria for MetS,
and the occurrence of MetS in females was 70.3 % (156/
222), and that of males is 49.7 % (153/308) (p < 0.001). The
proportions of smokers and drinkers were less frequent in
patients with MetS than in patients without MetS (p =
0.001 and 0.002 respectively). As expected, patients with
MetS had more prevalent family history of hypertension
and diabetes mellitus (p < 0.001). In MetS group, history
of medication use for hypertension and diabetes mellitus
were significantly more prevalent than that in non-MetS
group (p < 0.001). Moreover, among the five MetS compo-
nents, elevated waist circumference (WC), high fasting
blood glucose (FBG), high serum triglyceride (TG) and
low high density lipoprotein cholesterol (HDL-C) were
significantly more prevalent in the MetS group (p < 0.001).
In addition, body mass index (BMI), serum total choles-
terol (TC), lipoprotein cholesterol (LDL-C), uric acid
(UA) and fibrinogen were significantly higher for pa-
tients with MetS, compared to the patients without
MetS (all p < 0.05). There were no difference found
between these two groups regarding blood pressure,
neurologic impairment (National Institutes of Health
Stroke Scale (NIHSS) scores), temperature on admis-
sion and delayed time prior to admission and common
carotid arteries (CCAs) intima-media thickness (IMT).
Association of MetS and individual components with
short-term outcomes of the patients
At 30 days after the onset, 229 patients (modified Rankin
Scale (mRS) ≥3) or 231 patients (Barthal Index (BI) <60)
were identified with poor functional outcomes, and 23
patients died, and 31 patients suffered from recurrence.
Also, at 90 days after the onset, 221 patients (mRS ≥3) or
226 patients (BI <60) were identified with poor functional
outcomes, and 39 patients died, and 51 patients suffered
from recurrence. The results from univariate binary logistic
regression analysis are presented in Table 2. There were no
significant associations between MetS and stroke short
term outcomes. However hyperglycemia was found to be a
predictor for poor functional outcome and death whenever
at 30 or 90 days after the onset. No component was found
to account for stroke recurrence. However, low HDL-C was
identified as a decreased risk for poor functional outcome
at 90 days after the onset. Unexpected, elevated TG was
also found to be a decreased risk for poor functional
outcome whenever at 30 or 90 days after the onset. In
addition, there was no dose-response relationship between
the numbers of MetS components and short-term progno-
sis of ischemic stroke in this study as well.
In multivariate logistic regression analysis after adjusting
for age and sex, hyperglycemia was identified as an inde-
pendent risk factor for poor functional outcome whenever
at 30 or 90 days after the onset. The odds ratios (OR) of
hyperglycemia were 2.08 (95 % confidence interval (CI):
1.46–2.96) for functional outcome when assessed with
mRS ≥3 and 2.07 (95 % CI: 1.45–2.97) with BI <60 at
30 days after stroke onset respectively. For poor functional
outcome at 90 days after the onset, the OR of hypergly-
cemia were 2.00 (95 % CI: 1.40–2.84) when assessed with
mRS ≥3 and 2.12 (95 % CI: 1.47–3.04) with BI <60
respectively. Moreover, we reconfirmed that both low
HDL-C and elevated TG decrease the risks for poor func-
tional outcome whenever at 30 or 90 days after the onset
with multivariate regressive analysis after adjusting for age
and sex (Table 3).
Discussion
The prevalence of MetS in China has been steadily rising
in recent decades and reached 58.1 % in elderly Chinese
population [11]. A longitudinal study from Beijing Tongren
Hospital showed that the 5-year cumulative incidence of
MetS was 10.82 % in 2007 to 2012 [12]. In the United
States, the prevalence of MetS was 38.5 % in adults [13]
and it is 21.1 % in the French population [14]. As a
potential risk factor, MetS has been associated with an
increased risk of prevalent stroke [6]. The data from a
meta-analysis about 13 cohort studies showed that
subjects with MetS were 1.6-fold more likely to have
stroke than the ones without MetS [15] The occurrence
of MetS among the patients with acute ischemic stroke
in our study is 58.3 %. In the other two acute ischemic
stroke studies of Chinese, the occurrence of MetS was
51.4 and 57.29 %, respectively [8, 16]. There were more
female (70.3 %) than male (49.7 %) stroke patients with
MetS, which is consistent with the results from the other
study [4], and there were less stroke patients with smoking
or drinking in MetS+ group. However, the previous studies
tend to exhibit causal correlation between MetS and
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smoking and heavy alcohol consumption [17, 18]. We are
unsure about why the result of our current study differs
from that of previous ones; it may be due to the small
sample size of patients enrolled. Other risk factors were
further compared between the two major stroke groups
with or without MetS. In this study, we found that there
were positive and significant differences in the components
of MetS (high WC, elevated TG and depressed HDL-C,
hypertension and hyperglycemia) between two groups.
Dyslipidemia (elevated TG, decreased HDL-C and in-
creased LDL-C) and central obesity would enhance the
development and progress of cerebrovascular atheroscler-
osis, especially occlusive large artery diseases [19]. Hyper-
tension is the most important risk factor for all stroke
subtypes [20, 21]. It is known that insulin resistance is a
crucial factor to cause multiple proatherombotic effects
on the fibrinolytic system and vascular endothelium [22].
Numerous studies on the MetS and ischemic stroke
have been evaluated in the field of stroke prevention,
but the data about the impact of MetS and its individual
components on acute stroke prognosis is limited. Our
results agree with recent studies that MetS components
such as hyperglycemia are associated with the poor
short-term outcomes [7, 16, 23, 24].
Our results also showed that hyperglycemia is an inde-
pendent predictor for patient’s severe disability at 30 and
90 days rather than MetS itself, based on the multiple
logistic regression analysis after adjusting for age and sex.
Hyperglycemia was positively associated with the func-
tional outcome of acute ischemic stroke [25–28]. Several
explanations may account for the association between
hyperglycemia and poor functional outcomes after ische-
mic stroke. First, hyperglycemia may be directly toxic to
the ischemic neurons. In an experimental stroke model,
hyperglycemia aggravated the cellular acidosis in the is-
chemic penumbra and resulted in a greater infarct volume
[29]. Second, hyperglycemia may disrupt the blood-brain
barrier [30] and promote hemorrhagic infarct conversion
[31]. Third, hyperglycemia may be as a marker of severe
Table 1 Characteristics of patients with MetS+ and MetS
Characteristic MetS+ MetS− P value
n 309 221
Age (years) 68.8 ± 10.2 69.9 ± 12.4 0.248
Female, n (%) 156 (50.5) 66 (29.9) <0.001
Smoker, n (%) 104 (33.7) 107 (48.4) 0.001
Drinker, n (%) 39 (12.6) 51 (23.1) 0.002
Pre-history, n (%)
HTN 225 (72.8) 118 (53.4) <0.001
DM 82 (26.5) 10 (4.5) <0.001
CHD 25 (8.1) 21 (9.5) 0.275
TIA 8 (2.6) 9 (4.1) 0.339
Stroke 107 (34.6) 65 (29.4) 0.206
Treatment history, n (%)
Anti-HTN 201 (65.0) 95 (43.0) <0.001
Anti-DM 75 (24.3) 8 (3.6) <0.001
Family history, n (%)
HTN 108 (35.0) 53 (24.0) 0.007
DM 20 (6.5) 5 (2.3) 0.024
CHD 2 (0.6) 0 (0.0) 0.631
CVD 19 (6.1) 16 (7.2) 0.618
WC (cm)
Male 91.9 ± 7.2 82.9 ± 7.2 <0.001
Female 89.9 ± 9.2 82.9 ± 10.5 <0.001
BMI (kg/m2) 24.2 ± 3.2 21.4 ± 3.3 <0.001
SBP (mmHg) 151.8 ± 23.3 148.5 ± 23.6 0.109
DBP (mmHg) 86.1 ± 12.1 84.8 ± 12.5 0.232
Median NIHSS 4 (2 ~ 9) 4 (2 ~ 9) 0.562
Temperature (°C) 36.6 ± 0.5 36.6 ± 0.5 0.240
Prehospital delay (d) 6 (4, 48) 19 (4, 48) 0.128
Laboratory data
TG (mmol/L) 1.35 (1.02 ~ 1.90) 0.95 (0.74 ~ 1.17) <0.001
TC (mmol/L) 5.41 ± 1.30 5.09 ± 1.20 0.004
HDL-C (mmol/L) 1.08 ± 0.29 1.35 ± 0.35 <0.001
Male 0.99 ± 0.28 1.28 ± 0.33 <0.001
Female 1.17 ± 0.27 1.54 ± 0.31 <0.001
LDL-C (mmol/L) 3.62 ± 1.08 3.29 ± 1.06 0.001
Apo A, mmol/L 1.07 ± 0.22 1.18 ± 0.23 0.380
ApoB, mmol/L 1.07 ± 0.28 0.94 ± 0.27 0.928
FBG (mmol/L) 5.74 (4.91 ~ 6.95) 4.73 (4.27 ~ 5.27) <0.001
Creatinine (umol/L) 100.07 ± 35.53 98.69 ± 30.04 0.640
BUN (mmol/L) 5.34 ± 2.10 5.31 ± 2.22 0.854
UA (umol/L) 346.71 ± 134.53 324.56 ± 11.22 0.039
Table 1 Characteristics of patients with MetS+ and MetS
(Continued)
Fibrinogen (g/L) 3.63 ± 2.93 3.09 ± 1.20 0.011
CCA IMT (mm) 0.58 ± 0.50 0.56 ± 0.48 0.093
Data are acquired on admission and presented as means ± SDs or median (25th
to 75th percentiles) for all quantitative traits. The unpaired Student’s t-test or
Mann-Whitney test for continuous variables and the chi-square test or Fisher’s
exact test for categorical variables were used to compare the values of MetS and
non-MetS patients
HTN hypertention, DM diabetes mellitus, CHD coronary heart disease, TIA
transient ischemic attack, CVD cerebral vascular disease, WC waist
circumference, BMI body mass index, SBP systolic blood pressure, DBP diastolic
blood pressure, TG triglyceride, TC total cholesterol, HDL-C high density
lipoprotein cholesterol, LDL-C low density lipoprotein cholesterol, ApoA
Apolipoprotein A, ApoB Apolipoprotein B, FBG fasting blood glucose, BUN
blood urea nitrogen, UA uric acid, CCA IMT common carotid artery intima
media thickness
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Table 2 Impact of MetS and its individual components on stroke short-term outcomes
MetS Hyperglycemia Hypertension Low HDL-C Elevated TG Elevated WC No. of Components
n p OR 95 % CI p OR 95 % CI p OR 95 % CI p OR 95 % CI p OR 95 % CI p OR 95 % CI p OR 95 % CI
30 days after the onset
mRS ≥3 229 0.788 0.95 0.64 ~ 1.35 <0.001 2.03 1.02 ~ 1.06 0.847 0.85 0.47 ~ 1.53 0.12 0.76 0.54 ~ 1.07 0.001 0.46 0.29 ~ 0.72 0.485 0.87 0.59 ~ 1.28 0.568 0.96 0.82 ~ 1.11
BI <60 231 0.514 1.12 0.79 ~ 1.59 <0.001 2.10 1.48 ~ 2.99 0.618 0.86 0.48 ~ 1.55 0.12 0.76 0.53 ~ 1.08 <0.001 0.40 0.25 ~ 0.64 0.224 0.35 0.99 ~ 1.03 0.4.02 1.06 0.92 ~ 1.24
Death 23 0.805 1.16 0.44 ~ 2.85 0.010 3.34 1.33 ~ 8.35 0.014 0.25 0.09 ~ 0.76 0.612 1.25 0.52 ~ 2.99 0.064 0.15 0.02 ~ 1.12 0.647 0.80 0.31 ~ 2.05 0.608 0.91 0.63 ~ 1.31
Recurrence 31 0.084 0.52 0.24 ~ 1.09 0.801 0.91 0.43 ~ 1.94 0.957 0.97 0.28 ~ 3.36 0.35 1.43 0.68 ~ 3.01 0.156 0.41 0.12 ~ 1.41 0.157 0.57 0.27 ~ 1.24 0.221 0.82 0.59 ~ 1.13
90 days after the onset
mRS ≥3 221 0.387 0.86 0.60 ~ 1.22 <0.001 2.01 1.41 ~ 2.85 0.436 0.79 0.44 ~ 1.43 0.030 0.68 0.48 ~ 0.96 0.002 0.49 0.33 ~ 0.78 0.262 0.80 0.54 ~ 1.18 0.334 0.93 0.80 ~ 1.08
BI <95 226 0.502 1.13 0.80 ~ 1.60 <0.001 2.12 1.49 ~ 3.02 0.523 0.83 0.46 ~ 1.49 0.092 0.74 0.53 ~ 1.05 0.002 0.50 0.31 ~ 0.78 0.212 0.78 0.53 ~ 1.15 0.531 1.05 0.90 ~ 1.22
Death 39 0.225 0.63 0.30 ~ 1.33 0.025 2.18 1.10 ~ 4.31 0.099 0.45 0.17 ~ 1.16 0.855 1.07 0.54 ~ 2.11 0.061 0.31 0.09 ~ 1.05 0.097 0.55 0.28 ~ 1.11 0.223 0.83 0.62 ~ 1.11
Recurrence 51 0.984 1.02 0.56 ~ 1.86 0.775 0.92 0.51 ~ 1.66 0.870 0.92 0.35 ~ 2.46 0.248 1.42 0.78 ~ 2.59 0.698 1.15 0.57 ~ 2.35 0.708 0.88 0.45 ~ 1.71 0.611 1.07 0.83 ~ 1.38
Univariate binary logistic regression analysis was used to assess following variables, MetS, hyperglycemia, hypertension, low HDL-C, elevated TG and high WC to the contribution of stroke prognosis















Table 3 Impact of MetS and its individual components on stroke short-term outcomes, adjusted for age and sex
MetS Hyperglycemia Hypertension Low HDL-C Elevated TG Elevated WC No. of Components
n p OR 95 % CI p OR 95 % CI p OR 95 % CI p OR 95 % CI p OR 95 % CI p OR 95 % CI p OR 95 % CI
30 days after the onset
mRS 229 0.708 0.93 0.65 ~ 1.35 <0.001 2.08 1.46 ~ 2.96 0.051 0.55 0.30 ~ 1.00 0.055 0.70 0.49 ~ 1.01 0.003 0.49 0.31 ~ 0.79 0.717 0.93 0.61 ~ 1.40 0.474 1.06 0.90 ~ 1.24
BI 231 0.388 0.85 0.59 ~ 1.23 <0.001 2.07 1.45 ~ 2.97 0.167 0.64 0.34 ~ 1.20 0.048 0.69 0.48 ~ 0.99 <0.001 0.43 0.27 ~ 0.69 0.333 0.82 0.54 ~ 1.23 0.281 1.09 0.93 ~ 1.28
Death 23 0.660 1.23 0.50 ~ 3.03 0.003 2.59 1.07 ~ 6.28 0.012 0.25 0.09 ~ 0.74 0.863 0.93 0.39 ~ 0.98 0.124 0.20 0.03 ~ 1.54 0.976 0.99 0.37 ~ 2.62 0.739 1.07 0.72 ~ 1.58
Recurrence 31 0.271 0.66 0.31 ~ 1.39 0.586 0.81 0.39 ~ 1.72 0.739 0.81 0.23 ~ 2.81 0.685 1.17 0.55 ~ 2.46 0.181 0.44 0.13 ~ 1.47 0.164 0.57 0.26 ~ 1.26 0.239 1.22 0.88 ~ 1.71
90 days after the onset
mRS 221 0.404 0.86 0.60 ~ 1.23 <0.001 2.00 1.40 ~ 2.84 0.030 0.51 0.28 ~ 0.94 0.015 0.63 0.44 ~ 0.91 0.011 0.55 0.34 ~ 0.87 0.605 0.90 0.59 ~ 1.36 0.345 1.08 0.92 ~ 1.27
BI 226 0.466 0.87 0.60 ~ 1.26 <0.001 2.12 1.47 ~ 3.04 0.100 0.59 0.31 ~ 1.11 0.042 0.68 0.47 ~ 0.99 0.010 0.55 0.34 ~ 0.87 0.420 0.84 0.56 ~ 1.27 0.472 1.06 0.90 ~ 1.25
Death 39 0.578 0.82 0.41 ~ 1.65 0.082 1.82 0.93 ~ 3.56 0.058 0.39 0.15 ~ 1.03 0.676 0.86 0.42 ~ 1.73 0.121 0.38 0.11 ~ 1.29 0.301 0.68 0.33 ~ 1.42 0.412 1.14 0.84 ~ 1.55
Recurrence 51 0.902 1.04 0.57 ~ 1.90 0.755 0.911 0.51 ~ 1.64 0.758 0.86 0.32 ~ 2.30 0.220 1.45 0.80 ~ 2.62 0.479 1.28 0.64 ~ 2.56 0.965 0.99 0.50 ~ 1.94 0.573 0.93 0.72 ~ 1.21
Multiple logistic regression models were conducted to assess following variables, MetS, hyperglycemia, hypertension, low HDL-C, elevated TG and high WC to the contribution of stroke prognosis after adjustment for
age and sex















ischemic damage in patients with stroke. Patients with
severe stroke might develop hyperglycemia due to greater
release of stress hormones such as cortisol. These results
highlight the need for further study to determine whether
glucose lowering after stroke can improve functional out-
comes of ischemic stroke patients.
As for the additional implicative components for ische-
mic stroke, serum low HDL-C and high TG have negative
effects on 30 and/or 90 days prognosis in this study. How-
ever, cumulative data supported the idea that dyslipidemia
(low HDL-C and high TG) was directly related to the poor
outcomes of ischemic stroke patients [7, 32]. The main
reason for our paradoxical results might be due to the fact
that we did not control for all the other confounding
factors. Also, HDL-C particles can be assumed to have
pro-inflammatory and pro-atherogenic properties espe-
cially in the condition of chronic systemic inflammatory
response [33]. In addition, HDL-C increases formation of
lipid peroxide and oxidation of LDL-C and phospholipids
in patients with a history of coronary heart diseases [34].
Further studies with large sample size are needed to inves-
tigate these associations comprehensively.
Similar with other studies [8], there was no evidence in
present study to show that MetS was associated with recur-
rence and poor outcomes of acute ischemic stroke. Theor-
etically, MetS might have aggravated or deteriorated
patients’ condition and prognosis. MetS-related impair-
ments comprise hyperglycemia, chronic endothelial dam-
age, decreased endogenous fibrinolytic capacity, and
proinflammatory state, all of which may amplify cerebral is-
chemic damage and to hamper arterial recanalization [35].
However, there was no similar phenomenon in our study.
This might be explained by the following two reasons: a)
limited sample volume; and b) this study presented an off-
set effect of MetS components which showed a positive
effect in hyperglycemia but negative in hypertension, low
HDL-C and elevated TG on the short term outcomes of
cerebral infarction. These components might offset each
other, which may even lead to irrelevance between MetS
and stroke short-term prognosis. Additionally, no dose-
response relationship between the numbers of MetS com-
ponents and short-term prognosis of ischemic stroke was
found in this study.
There were several limitations in our study. First, our
data was based on one hospital-based cohort, and the
small sample size may not be appropriate to generalize.
Second, although the patients with acute ischemic stroke
admitted to the Department of Neurology were consecu-
tively registered, the patients who were sent to the
Emergency Department and died soon there before
hospitalization were excluded. Therefore, it is possible
that the case fatality and other poor outcomes from our
study were under-estimated to some extent. Third, no
data was gathered on long-term outcomes for these
patients. Despite these limitations, our pilot study did pro-
vide some important information about the occurrence of
MetS and the effects of MetS and its components on the
short-term prognosis of patients with acute ischemic
stroke. We believe that it would be useful for further study
because MetS and its components are modifiable risk fac-
tors for ischemic stroke. Above all, a multi-center pro-
spective cohort study is needed to further investigate the
relationship between MetS and stroke for its primary and
secondary prevention.
Conclusion
The occurrence of MetS among patients with acute is-
chemic stroke in our study is 58.3 %. MetS itself may
not be predictive of the short-term prognosis of patients,
while hyperglycemia is a significant predictor for poor
functional outcomes. Our data provided valuable infor-
mation toward better understanding of individuals who
are at increased risk of ischemic stroke and reaffirmed
the need to develop preventive strategies directed to the




A hospital-based retrospective study was performed from
January 1, 2006 to December 31, 2006. During this period,
a total of 1377 consecutive stroke patients were admitted
to the Department of Neurology, the Second Affiliated
Hospital of Guangzhou Medical University. Five hundred
and thirty patients with acute ischemic stroke (within
7 days from symptom onset) were eligible to be recruited
in this study (Fig. 1). Criteria for exclusions were patients
who experienced the onset of stroke more than 7 days
before hospitalization, or who were diagnosed with “silent
stroke” or who were sent to the Emergency Department
and died soon there before hospitalization. Patients with
cerebral hemorrhage, subarachnoid hemorrhage, brain
tumor or other central nervous system disorders were also
excluded. This study was approved by the Hospital Insti-
tutional Ethics Committee. Also, written informed con-
sent to participate in the study was obtained from each
patient or his/her relative if patients could not consent by
themselves.
All the subjects presented clinical characteristics of acute
ischemic stroke, confirmed by cranial computed tomog-
raphy and/or magnetic resonance imaging/angiography.
Assessments
Data collection was performed by using a standardized
questionnaire based on an extensive manual and follow-
up information. General information, present illness, pre-
vious history (including hypertension, diabetes mellitus,
coronary heart disease, transient ischemic attack and
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stroke), personal history (including cigarette smoking and
drinking habits), family history (including hypertension,
diabetes mellitus, coronary heart diseases and cerebrovas-
cular diseases), the data of physical examination, labora-
tory and imaging results were all recorded for all subjects
enrolled in this study. Carotid ultrasonography, transcra-
nial doppler and magnetic resonance angiography were
used to evaluate brain-supplying arteries. Cardiac diagnos-
tic test such as electrocardiography and transthoracic
echocardiography were used to identify cardioembolic
stroke.
All the baseline clinical characteristics were recorded
at the time of admission while venous blood samples
were extracted after 12 h fasting time at the second day
of hospitalization. Serum glucose, TG, TC, HDL-C,
LDL-C, apolipoprotein (Apo)-A, Apo-B, creatinine, urea
nitrogen and UA were measured by Hitachi 7600 auto-
matic analyzer (Hitachi Instruments Corporation, Tokyo,
Japan). Blood fibrinogen was evaluated by turbidimetry
with the use of CA7000 (Sysmex, Japan).
Waist circumference was measured by a measuring
tape positioned at the narrowest part between the lowest
rib margin and the high point of the iliac crest after a
normal expiratory breath. Body height was measured,
without wearing shoes, with an accuracy of 0.1 cm, using
a calibrated stadiometer. Body weight was measured to
the nearest 0.1 kg, wearing underwear, with a calibrated
electronic scale. BMI was calculated by dividing weight
by height squared (kg/m2). Blood pressure was measured
on the right arm at heart level with a mercury sphygmo-
manometer after being seated for at least 5 min. CCAs
IMT was defined as the distance between the edges of
the lumen-intima interface and the media-adventitia
interface of the far wall. In this study, IMT of both
CCAs were uniformly measured by one sonographer,
using color doppler ultrasonography (ALOKA prosound
α5, Hitachi Instruments Corporation, Tokyo, Japan) with
a 7.5 ~ 10.0 MHz transducer frequency in 3 days after
admission.
Clinical assessments consisted of the NIHSS, mRS and
BI, which were performed by four well-trained neurolo-
gists who were blinded to magnetic resonance imaging
results. The score of NIHSS is from 0 (normal) to 42,
measured at the admission. Functional outcome was
assessed with mRS and BI at 30 and 90 days after the
occurrence of stroke. Patients who died scored 6 in the
mRS. A mRS of 0 to 2, or a BI score of 95 to 100 was
considered as a favorable outcome, and mRS ≥3 or BI <60
was used as cutoff scores to defined poor outcome [36].
Recurrent stroke was defined as any new episode of
focal cerebral dysfunction persisting >24 h, which oc-
curred after a period of unequivocal neurological stability
or improvement. This definition excluded any new deficit
that occurred within 24 h or that was thought to be attrib-
utable to edema, mass effect, brain shift syndrome, or
hemorrhagic transformation of the incident infarct.
Patients were followed up with hospital visits during
the first and three months after the stroke event. Pa-
tients who were unable to attend the scheduled visits or
had migrated from our city were contacted by telephone.
In case of death, dates and causes were registered by
gathering information from relatives or records kept by
hospitals.
Definition of metabolic syndrome
Patients were classified into two groups at baseline based
on whether or not the diagnostic criteria for MetS were
met. According to the American Heart Association/
National Heart, Lung, and Blood Institute definition for
MetS [37], MetS was defined as the presence of any three
of the following five risk components: (i) elevated WC
(male ≥ 85 cm, female ≥ 80 cm), (ii) TG ≥ 1.70 mmol/L, (iii)
HDL-C < 1.0 mmol/L (male) or <1.3 mmol/L (female), (iv)
hypertension: systolic pressure ≥ 130 mmHg, diastolic pres-
sure ≥ 85 mmHg or need for anti-hypertensive medication
and (v) hyperglycemia: FBG ≥ 5.6 mmol/L (≥100 mg/dL) or
need for anti-hyperglycemic medication.
Statistical analysis
The data was entered duplicatedly into a stroke data
bank built with Microsoft Visual FoxPro 6.0 and checked
for completeness, logical consistency and duplication,
and then locked in. Statistical analyses were performed
with the Statistical Package for Social Sciences for
Windows, version 13.0 (SPSS, Inc, Chicago, IL, USA).
Fig. 1 Study design
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Measurement data were summarized by mean ± stand-
ard deviation or as median and 25th and 75th quartile
values. The differences of baseline characteristics of the
patients were compared with the unpaired Student’s
t-test or Mann-Whitney test for continuous variables and
the chi-square test or Fisher’s exact test for categorical
variables. To generate the odds ratio, univariate binary
logistic regression analysis was conducted to assess MetS,
hyperglycemia, hypertension, low HDL-C, elevated TG
and high WC to the contribution of stroke prognosis.
Further, multiple logistic regression models were conducted
after adjusting for age and sex.
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